Get the Stockscreener App
0.4071
19.86%
-0.1009
Curis Inc stock is traded at $0.4071, with a volume of 1.32M.
It is down -19.86% in the last 24 hours and down -63.65% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$0.508
Open:
$0.4467
24h Volume:
1.32M
Relative Volume:
3.57
Market Cap:
$987.25K
Revenue:
$7.06M
Net Income/Loss:
$-21.17M
P/E Ratio:
-0.017
EPS:
-23.879
Net Cash Flow:
$-28.95M
1W Performance:
-39.35%
1M Performance:
-63.65%
6M Performance:
-96.56%
1Y Performance:
-98.70%
1-Day Range:
$0.325
$0.4533
1-Week Range:
$0.325
$0.6899
52-Week Range:
$0.325
$33.60
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
0.4071 | 987.25K | 7.06M | -21.17M | -28.95M | -23.88 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Curis priced a USD 5.6 million offering and Curis stock fell 10.61 percent - AD HOC NEWS
Curis stock fell 5.07 percent as targets reached USD 65 - AD HOC NEWS
Curis stock trades 1.45 percent below EUR 0.69 prior close - AD HOC NEWS
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer - GlobeNewswire Inc.
Curis Inc. stock holds steady as investors weigh recent clinical and financial signals - AD HOC NEWS
CRIS Stock Price, Quote & Chart - ChartMill
Curis Inc. (NASDAQ:CRIS) - intelligentinvestor.com.au
Curis Inc. (CRIS) Key Financial Ratios – Valuation, Profitability & More - Value Research
CRIS Q2 2026 Earnings: 49.73% EPS Beat Fails to Prevent 2.82% Stock DeclineEarnings Quality Analysis - vinanet.vn
Curis stock context as market data stays elusive - ad-hoc-news.de
Curis Inc. (CRIS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Curis (CRIS) Earnings Snapshot: EPS Falls Short of Its Estimate at the Close; Market Move: The Stock Loses 1.86% for the Current SessionEarnings Miss Alert - vinanet.vn
Curis (CRIS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark for This Review; Stock Move: The Stock Gains 1.18% in the Latest SessionAnnual Financial Report - dars.gov.et
Curis (CRIS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark for This Review; Stock Move: The Stock Gains 1.18% in the Latest SessionFiscal Year Earnings - vinanet.vn
Curis (CRIS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark for This Review; Stock Move: The Stock Gains 1.18% in the Latest SessionEarnings Call Highlights - dars.gov.et
Curis (CRIS) Results Versus Estimates: EPS Falls Short of Its Estimate in Latest Trading; Trading Move: Shares Finish 5.56% Down in the Current UpdateEarnings Deceleration Risk - vinanet.vn
Curis (CRIS) Price Update: Slides 5.56% to $1.70; Boundary Check: the $1.61 to $1.78 Range Remains in Focus for the Current SessionDark Pool Volume - vinanet.vn
Analysts Are Bullish on These NA Stocks: Curis (CRIS), Canadian National Railway (CNI) - The Globe and Mail
CRIS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $43 - GuruFocus
Curis announces pricing of $5.6M public offering - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks - TipRanks
CRIS Q1 2026 Earnings: EPS Misses by 206.37% as Stock Slides 3.74%Profit Growth Outlook - vinanet.vn
Curis Inc. (CRIS) Slips 3.74% to $1.80: Key Support and Resistance Levels in FocusFear Greed Extreme - vinanet.vn
Curis Inc. (CRIS) Slips 3.74% to $1.80: Key Support and Resistance Levels in FocusInvestment Factor - dars.gov.et
Curis Stock Price Forecast. Should You Buy CRIS? - StockInvest.us
Curis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Curis: Q2 Earnings Snapshot - AOL.com
Curis: Q2 Earnings Snapshot - Caledonian Record
Curis: Q2 Earnings Snapshot - KING5.com
Curis: Q2 Earnings Snapshot - KTVB
CURIS INC 10-Q Summary: Revenue $0 Net income ($8.58M), EPS ($4.02) — 10-Q Summary - TradingView
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Curis: Q2 Earnings Snapshot - Yahoo Finance
Curis Prices $5.6 Million Public Offering With Healthcare-Focused Institutional Investors - marketscreener.com
CRIS Looks 91.8% Undervalued on GF Value™ Amid Unprofitability C - GuruFocus
Curis prices $5.6 million public offering at $1.50 per share By Investing.com - Investing.com Canada
Curis prices $5.6 million public offering at $1.50 per share - Investing.com
Curis prices $5.6 million public offering at $1.50 per share By Investing.com - Investing.com UK
Curis, Inc. Announces Pricing of $5.6 Million Public Offering - PR Newswire
CURIS INC SEC Filing (Aug 13, 2026) - Stock Titan
Curis prices $5.6M public offering to fund deve... - Pluang
Curis Inc (CRIS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IPO Databook: Curis (CRIS US)Aug 2026 - smartkarma.com
Curis (CRIS) seeks cash via best-efforts stock and warrant offering amid going-concern risk - Stock Titan
Curis Inc (CRIS) Stock News Today - TradingKey
Curis Inc expected to post a loss of $7.84 a shareEarnings Preview - TradingView
Curis Inc (CRIS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curis, Inc. (CRIS) stock price, news, quote and history - au.finance.yahoo.com
Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework - finance.yahoo.com
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):